Lumos Pharma Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Lumos Pharma zullen naar verwachting dalen met respectievelijk 1.8% en 11.6% per jaar, terwijl de winst per aandeel naar verwachting zal groeien met 41.3% per jaar.

Belangrijke informatie

-11.6%

Groei van de winst

41.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	-1.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Winst- en omzetgroeiprognoses

NasdaqGM:LUMO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1	-51	N/A	-49	3
12/31/2025	1	-43	N/A	-41	4
12/31/2024	6	-30	N/A	-34	4
9/30/2024	2	-35	-32	-32	N/A
6/30/2024	1	-36	-34	-34	N/A
3/31/2024	2	-37	-35	-35	N/A
12/31/2023	2	-34	-31	-31	N/A
9/30/2023	2	-33	-30	-30	N/A
6/30/2023	2	-32	-27	-27	N/A
3/31/2023	2	-31	-28	-28	N/A
12/31/2022	2	-31	-27	-27	N/A
9/30/2022	1	-28	-27	-27	N/A
6/30/2022	1	-29	-28	-28	N/A
3/31/2022	0	-30	-27	-27	N/A
12/31/2021	0	-30	-30	-30	N/A
9/30/2021	0	-27	-31	-31	N/A
6/30/2021	0	-18	-23	-23	N/A
3/31/2021	0	-15	-30	-30	N/A
12/31/2020	0	-6	-23	-23	N/A
9/30/2020	0	-7	-19	-19	N/A
6/30/2020	0	-12	-21	-21	N/A
3/31/2020	0	-10	-10	-10	N/A
12/31/2019	N/A	-13	-9	-9	N/A
9/30/2019	N/A	-11	-8	-8	N/A
12/31/2018	N/A	-11	-11	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat LUMO de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat LUMO de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat LUMO de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van LUMO zal naar verwachting de komende 3 jaar dalen ( -1.8% per jaar).

Hoge groei-inkomsten: De omzet van LUMO zal naar verwachting de komende 3 jaar dalen ( -1.8% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van LUMO naar verwachting over 3 jaar hoog zal zijn

Lumos Pharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 11%

Price target increased by 15% to US$23.33

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target increased by 13% to US$20.25

Consensus revenue estimates increase by 43%, EPS downgraded

Consensus revenue estimates increase by 99%

Recent updates

Lumos Pharma, Inc. Announces Updated Phase 2 OraGrowtH Data Presented at ESPE 2024

Double Point Ventures LLC entered into a definitive merger agreement to acquire Lumos Pharma, Inc. (NasdaqGM:LUMO) for $36.9 million.

Lumos Pharma, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Lumos Pharma, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 15% to US$23.33

Lumos Pharma, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting

Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Price target increased by 13% to US$20.25

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.92 loss in 1Q 2022)

Consensus revenue estimates increase by 43%, EPS downgraded

Lumos Pharma, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

New minor risk - Share price stability

Insider recently sold US$611k worth of stock

Insider recently bought US$455k worth of stock

Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Consensus revenue estimates increase by 99%

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 17%

Lumos Pharma, Inc. to Report Fiscal Year 2022 Results on Mar 01, 2023

Consensus revenue estimates increase by 66%

Price target decreased to US$21.83

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma, Inc. (NasdaqGM:LUMO) announces an Equity Buyback for $3 million worth of its shares.

Lumos Pharma announces new buyback program

Lumos Pharma, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Lumos Pharma, Inc. Announces Clinical Development Updates

Price target decreased to US$25.00

Lumos Pharma, Inc. Reaches 50% Randomization Milestone in Phase 2 Oragrowth210 Trial Evaluating Oral Lum-201 in Pghd

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$25.00

Lumos Pharma, Inc. to Report Fiscal Year 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.90 loss per share (vs US$0.21 profit in 3Q 2020)

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Independent Director recently bought US$56k worth of stock

First half 2021 earnings released: US$2.08 loss per share (vs US$1.08 loss in 1H 2020)

Price target decreased to US$27.67

Lumos Pharma, Inc. Announces New Data Highlights from Three Patients with Pediatric Growth Hormone Deficiency

Chief Medical Officer has left the company

Lumos Pharma, Inc. Announces Results of Peer-Reviewed Analyses of Data from Two Prior Pediatric Growth Hormone Deficiency

New 90-day low: US$14.97

Independent Director has left the company

Lumos Pharma, Inc. to Report Fiscal Year 2020 Results on Mar 09, 2021

Lumos Pharma, Inc. Announces Board Changes

Lumos Pharma, Inc. Announces Resignation of Eugene P. Kennedy as Chief Medical Officer, Effective March 6, 2021

New 90-day high: US$17.47

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

New 90-day high: US$15.80

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Analysts increase revenue estimates to US$60.7k

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Lumos Pharma, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Analysts lower revenue estimates to US$2.65m

Lumos Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten